The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Prognostic Significance of [18F]-Misonidazole Positron Emission Tomography–Detected Tumor Hypoxia in Patients With Advanced Head and Neck Cancer Randomly Assigned to Chemoradiation With or Without Tirapazamine: A Substudy of Trans-Tasman Radiation Oncology Group Study 98.02
Abstract
Purpose: To determine the association between tumor hypoxia, treatment regimen, and locoregional failure (LRF) in patients with stage III or IV squamous cell carcinoma of the head and neck randomly assigned to radiotherapy (70 Gy in 35 fractions over 7 weeks) plus either tirapazamine and cisplatin in weeks 1, 4, and 7 and tirapazamine alone in weeks 2 and 3 (TPZ/CIS) or cisplatin and infusional fluorouracil during weeks 6 and 7 (chemoboost). Patients and Methods: Forty-five patients were enrolled onto a hypoxic imaging substudy of a larger randomized trial. Pretreatment and midtreatment [18 F]-fluoromisonidazole positron emission tomography scans (FMISO-PET) were performed 2 hours after tracer administration, with qualitative scoring of uptake in both primary tumors and nodes. Results: Thirty-two patients (71%) had detectable hypoxia in either or both primary and nodal disease. In patients who received chemoboost, one of 10 patients without hypoxia had LRF compared with eight of 13 patients with hypoxia; the risk of LRF was significantly higher in hypoxic patients (exact log-rank, P = .038; hazard ratio [HR] = 7.1). By contrast, in patients who received the TPZ/CIS regimen, only one of 19 patients with hypoxic tumors had LRF; risk of LRF was significantly higher in chemoboost patients (P = .001; HR = 15). Similarly, looking at the primary site alone, in patients with hypoxic primaries, zero of eight patients treated with TPZ/CIS experienced failure locally compared with six of nine patients treated with chemoboost (P = .011; HR = 0). Conclusion: Hypoxia on FMISO-PET imaging, in patients receiving a nontirapazamine-containing chemoradiotherapy regimen, is associated with a high risk of LRF. Our data provide the first clinical evidence to support the experimental observation that tirapazamine acts by specifically targeting hypoxic tumor cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gray, L. H., Conger, A. D., Ebert, M., Hornsey, S., & Scott, O. C. A. (1953) · The British Journal of Radiology · doi:10.1259/0007-1285-26-312-638 · Cited by 2,158
Adelstein, D. J., Li, Y., Adams, G. L., Wagner, H., Kish, J. A., Ensley, J. F., Schuller, D. E., & Forastiere, A. A. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.008 · Cited by 1,748
Brizel, D. M., Albers, M. E., Fisher, S. R., Scher, R. L., Richtsmeier, W. J., Hars, V., George, S. L., Huang, A. T., & Prosnitz, L. R. (1998) · New England Journal of Medicine · doi:10.1056/nejm199806183382503 · Cited by 1,127
Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck
Brizel, D. M., Sibley, G. S., Prosnitz, L. R., Scher, R. L., & Dewhirst, M. W. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(97)00101-6 · Cited by 1,068
Calais, G., Alfonsi, M., Bardet, E., Sire, C., Germain, T., Bergerot, P., Rhein, B., Tortochaux, J., Oudinot, P., & Bertrand, P. (1999) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/91.24.2081 · Cited by 1,060
Nordsmark, M., Overgaard, M., & Overgaard, J. (1996) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(96)91811-3 · Cited by 942
Gatenby, R. A., Kessler, H. B., Rosenblum, J. S., Coia, L. R., Moldofsky, P. J., Hartz, W. H., & Broder, G. J. (1988) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(88)90002-8 · Cited by 798
(2001) · PubMed · Cited by 605
SR-4233: A new bioreductive agent with high selective toxicity for hypoxic mammalian cells
Zeman, E. M., Brown, J. M., Lemmon, M. J., Hirst, V. K., & Lee, W. W. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90267-1 · Cited by 402
Koukourakis, M. I., Giatromanolaki, A., Sivridis, E., Simopoulos, C., Turley, H., Talks, K., Gatter, K. C., & Harris, A. L. (2002) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(02)02848-1 · Cited by 361
Cited by
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
Hypoxia in cancer: significance and impact on clinical outcome
Vaupel, P., & Mayer, A. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9055-1 · Cited by 2,240
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
Chemical Design and Synthesis of Functionalized Probes for Imaging and Treating Tumor Hypoxia
Liu, J.-N., Bu, W., & Shi, J. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00525 · Cited by 838
Rischin, D., Young, R. J., Fisher, R., Fox, S. B., Le, Q.-T., Peters, L. J., Solomon, B., Choi, J., O'Sullivan, B., Kenny, L. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.2904 · Cited by 737
Self-citationHypoxic Radiosensitization: Adored and Ignored
Overgaard, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7878 · Cited by 619
Imaging hypoxia to improve radiotherapy outcome
Horsman, M. R., Mortensen, L. S., Petersen, J. B., Busk, M., & Overgaard, J. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.171 · Cited by 614
Clinical update on head and neck cancer: molecular biology and ongoing challenges
Alsahafi, E., Begg, K., Amelio, I., Raulf, N., Lucarelli, P., Sauter, T., & Tavassoli, M. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1769-9 · Cited by 525
Skeletal PET with18F-Fluoride: Applying New Technology to an Old Tracer
Grant, F. D., Fahey, F. H., Packard, A. B., Davis, R. T., Alavi, A., & Treves, S. T. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.106.037200 · Cited by 520
Krohn, K. A., Link, J. M., & Mason, R. P. (2008) · Journal of Nuclear Medicine · doi:10.2967/jnumed.107.045914 · Cited by 506
Therapeutic targeting of the hypoxic tumour microenvironment
Singleton, D. C., Macann, A., & Wilson, W. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00539-4 · Cited by 484
Liu, Y., Liu, Y., Bu, W., Cheng, C., Zuo, C., Xiao, Q., Sun, Y., Ni, D., Zhang, C., Liu, J., et al. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201500478 · Cited by 425
Walsh, J. C., Lebedev, A., Aten, E., Madsen, K., Marciano, L., & Kolb, H. C. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5378 · Cited by 420
Rischin, D., Peters, L. J., O'Sullivan, B., Giralt, J., Fisher, R., Yuen, K., Trotti, A., Bernier, J., Bourhis, J., Ringash, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4449 · Cited by 380
Self-citationUse of PET and PET/CT for Radiation Therapy Planning: IAEA expert report 2006–2007
MacManus, M., Nestle, U., Rosenzweig, K. E., Carrio, I., Messa, C., Belohlavek, O., Danna, M., Inoue, T., Deniaud-Alexandre, E., Schipani, S., et al. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2008.11.008 · Cited by 367
Imaging tumour hypoxia with positron emission tomography
Fleming, I. N., Manavaki, R., Blower, P. J., West, C., Williams, K. J., Harris, A. L., Domarkas, J., Lord, S., Baldry, C., & Gilbert, F. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.610 · Cited by 330
Emerging biomarkers in head and neck cancer in the era of genomics
Kang, H., Kiess, A., & Chung, C. H. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.192 · Cited by 310
Krause, M., Dubrovska, A., Linge, A., & Baumann, M. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.02.002 · Cited by 305
Hypoxia Positron Emission Tomography Imaging With 18F-Fluoromisonidazole
Lee, S. T., & Scott, A. M. (2007) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2007.07.001 · Cited by 283
Zips, D., Zöphel, K., Abolmaali, N., Perrin, R., Abramyuk, A., Haase, R., Appold, S., Steinbach, J., Kotzerke, J., & Baumann, M. (2012) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2012.08.019 · Cited by 280
Spence, A. M., Muzi, M., Swanson, K. R., O'Sullivan, F., Rockhill, J. K., Rajendran, J. G., Adamsen, T. C. H., Link, J. M., Swanson, P. E., Yagle, K. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4995 · Cited by 277
Targeting Hypoxia to Improve Non–Small Cell Lung Cancer Outcome
Salem, A., Asselin, M.-C., Reymen, B., Jackson, A., Lambin, P., West, C. M. L., O’Connor, J. P. B., & Faivre-Finn, C. (2018) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djx160 · Cited by 266
Toustrup, K., Sørensen, B. S., Nordsmark, M., Busk, M., Wiuf, C., Alsner, J., & Overgaard, J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1182 · Cited by 255
Eustace, A., Mani, N., Span, P. N., Irlam, J. J., Taylor, J., Betts, G. N. J., Denley, H., Miller, C. J., Homer, J. J., Rojas, A. M., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0542 · Cited by 240
“Evidence suggests that hypoxic tumors benefit most from hypoxia-modifying therapy (4-8).”
PET/CT imaging in cancer: current applications and future directions
Farwell, M. D., Pryma, D. A., & Mankoff, D. A. (2014) · Cancer · doi:10.1002/cncr.28860 · Cited by 230
Yang, S., Tang, Z., Hu, C., Zhang, D., Shen, N., Yu, H., & Chen, X. (2019) · Advanced Materials · doi:10.1002/adma.201805955 · Cited by 210
Borad, M. J., Reddy, S. G., Bahary, N., Uronis, H. E., Sigal, D., Cohn, A. L., Schelman, W. R., Stephenson, J., Chiorean, E. G., Rosen, P. J., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7504 · Cited by 197
“A number of positron emission tomography imaging agents are being investigated as potential identifiers of tumor hypoxia.(20,21) On the basis of the findings in this phase II study, a global phase III clinical trial (MAESTRO; NCT01746979) comparing gemcitabine plus TH-302 at 340 mg/m(2) versus gemcitabine plus placebo…”
Hicks, K. O., Siim, B. G., Jaiswal, J. K., Pruijn, F. B., Fraser, A. M., Patel, R., Hogg, A., Liyanage, H. D. S., Dorie, M. J., Brown, J. M., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1439 · Cited by 132
Targeting hypoxic tumour cells to overcome metastasis
Bennewith, K. L., & Dedhar, S. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-504 · Cited by 109
“A common issue with the Phase III TPZ trials is the failure to pre-select patients with significant numbers of hypoxic cells in their tumours for treatment with the hypoxia-activated drug [55].”
Hunter, F. W., Young, R. J., Shalev, Z., Vellanki, R. N., Wang, J., Gu, Y., Joshi, N., Sreebhavan, S., Weinreb, I., Goldstein, D. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1107 · Cited by 82
Self-citationRiedl, C. C., Brader, P., Zanzonico, P. B., Chun, Y. S., Woo, Y., Singh, P., Carlin, S., Wen, B., Ling, C. C., Hricak, H., et al. (2008) · Radiology · doi:10.1148/radiol.2482071421 · Cited by 41
Characterization of Hypoxia in Malignant Pleural Mesothelioma with FMISO PET-CT
Francis, R. J., Segard, T., Morandeau, L., Lee, Y. C. G., Millward, M. J., Segal, A., & Nowak, A. K. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.07.015 · Cited by 34
Metadata
- Authors
- Rischin, D., Hicks, R. J., Fisher, R., Binns, D., Corry, J., Porceddu, S., & Peters, L. J.
- Venue
- Journal of Clinical Oncology
- Published
- 2006-05-01
- Volume
- 24
- Issue
- 13
- Pages
- 2098-2104
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2136800292
- Cited by
- 541
- References
- 34
- FWCI
- 40.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.